L1-79
/ Yamo Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
July 31, 2024
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2 | N=58 | Completed | Sponsor: Yamo Pharmaceuticals LLC | Active, not recruiting ➔ Completed
Trial completion • Autism Spectrum Disorder • Genetic Disorders
January 01, 2024
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2 | N=58 | Active, not recruiting | Sponsor: Yamo Pharmaceuticals LLC
Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders
November 18, 2023
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2 | N=58 | Active, not recruiting | Sponsor: Yamo Pharmaceuticals LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • Autism Spectrum Disorder • Genetic Disorders
January 27, 2023
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2 | N=50 | Recruiting | Sponsor: Yamo Pharmaceuticals LLC | Trial completion date: Mar 2023 ➔ Feb 2024 | Trial primary completion date: Feb 2023 ➔ Jan 2024
Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders
January 26, 2022
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2; N=50; Recruiting; Sponsor: Yamo Pharmaceuticals LLC; Not yet recruiting ➔ Recruiting
Enrollment open • Autism Spectrum Disorder • Genetic Disorders
October 05, 2021
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2; N=50; Not yet recruiting; Sponsor: Yamo Pharmaceuticals LLC
Clinical • New P2 trial • Autism Spectrum Disorder • Genetic Disorders
1 to 6
Of
6
Go to page
1